Healthcare professionals

AfA is here to help you care for and manage patients living with HIV/AIDS. Access our team of clinical HIV experts to get support, ask for advice and discuss complex clinical challenges. Explore our protocols, guidelines, publications and clinical intelligence.


CPD online training

Gain HIV management skills.

Online modular training for doctors and other healthcare professionals in HIV medicine offers a practical solution to gain HIV management skills. It is particularly suitable for those working outside of the major centres.

You can complete individual modules or the full training programme.

  • The modules cover the basics of HIV management and reflect current best practice, both nationally and internationally.
  • Each module is CPD-accredited with a CPD certificate issued online following successful answering of several multiple-choice questions.
  • All the modules will be updated annually.
  • There will be a dedicated annual HIV update module based on new guidelines and advances in HIV management.

Registration on the course is free of charge and is open to all doctors as well as other interested healthcare professionals.

Please go here to register, using your professional council registration number, and follow the simple instructions. If you do not have a professional council number your ID number may be used.

The course has been developed by Professor Gary Maartens, who is an acknowledged expert in HIV management and has participated in the development of HIV treatment guidelines both nationally and internationally. He has been involved in teaching and research in HIV medicine for many years and has been a senior consultant on the AfA Clinical Advisory Committee since its inception in 1998.

Publications and Presentations

AfA has spoken at and participated in local and international conferences, had its collaborative research published and been invited to speak at a variety of organisations. Our approach is to share our expertise on the clinical, programmatic and behavioural aspects of managing HIV in different settings freely.


September 2021

  • The Odyssey trial, a journey for children
  • The role of abacavir in adults
  • The question of TLD as second-line ART

December 2020

  • HIV and the risk of COVID-19 and its complications
  • Managing weight gain associated with Dolutegravir

July 2020

  • Update on Dolutegravir for children
  • Isoniazid preventive therapy in pregnancy: update

October 2019

  • The importance of the gut microbiota to health in HIV
  • Update on risk for neural tube disorders for women on Dolutegravir at conception: downgraded but real risk
  • No clinically significant interaction between Dolutegravir and Valproate

March 2019

  • Tuberculosis Preventive Therapy for Adults
  • Undetectable = Untransmittable (U=U)
  • Important drug-drug interactions with Dolutegravir

July 2018

  • Potential safety issue affecting HIV+ women taking Dolutegravir at the time of conception
  • New WHO guidelines for induction therapy in cryptococcal meningitis
  • Treatment of cytomegalovirus (CMV) retinitis
  • Isoniazid preventive therapy (IPT) in pregnancy

February 2008

  • AfA clinical newsletter – issue 19
  • Double-boosted protease inhibitor therapy for salvage ART: lack of evidence of benefit
  • Diagnosing and treating smear negative and extrapulmonary tuberculosis in HIV-infected patients
  • Atazanavir in pregnancy
  • Fluconazole and pregnancy
  • Nutritional Management of the HIV-positive patient ‘facts, fallacies and folk-lore’
  • Monitoring patients on Tenofovir – an update
  • Completing the AfA application form

February 2018

  • Dolutegravir in pregnancy
  • Is there still a role for nevirapine?
  • The Xpert MTB/RIF Ultra: increased sensitivity for diagnosing HIV-associated TB with a small increase in false positive results
  • Treatment of multi-drug resistant gonorrhoea – what’s in the pipeline?

September 2017

  • Severe efavirenz-induced ataxia and encephalopathy
  • Prolonged post-treatment virologic control in a South African HIV+ child after early antiretroviral therapy – implications for the future?
  • The DAWNING trial: Dolutegravir in second-line ART

March 2017

  • Early ART initiation as a factor in combating antibiotic resistance
  • Dolutegravir: not as monotherapy
  • BREATHER –  Can HIV+ youth safely have a weekend off their antiretroviral medication?
  • Diagnosing ‘elite controllers’

October 2016

  • Rifabutin dosing with protease inhibitors
  • Drug-drug interactions involving second generation NNRTIs
  • Pure red cell aplasia in HIV

June 2016

  • Dolutegravir: its use in adult patients
  • Dolutegravir: its use in paediatric patients
  • Drug-drug interactions between antiretrovirals and Itraconazole
  • Zika and HIV